Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules.

The A*0201, A *0202, A*0203, A*0206, and A*6802 binding capacity of single amino acid substitution analogs of known A2-supertype binding peptides and of large nonredundant peptide libraries was measured. The results were utilized to rigorously define the peptide binding specificities of these A2-supertype molecules. Although each molecule was noted to have unique preferences, large overlaps in specificity were found. The presence of L, I, V, M, A, T, and Q residues in position 2, and L, I, V, M, A, and T residues at the C-terminus of peptide ligands were tolerated by all molecules. Likewise, whereas examination of secondary influences on peptide binding revealed allele specific preferences, shared features could also be identified. These shared features were utilized to define an A2-supermotif and were noted to correlate with crossreactivity. Over 70% of the peptides that bound A *0201 with high affinity were found to bind at least two other A2-supertype molecules. Because the A2-supertype molecules studied herein cover the variants most common in different major ethnicities, these findings have important implications for epitope-based approaches to vaccination, immunotherapy, and the monitoring of immune responses.

[1]  K. Cao,et al.  High and intermediate resolution DNA typing systems for class I HLA-A, B, C genes by hybridization with sequence-specific oligonucleotide probes (SSOP). , 1999, Reviews in immunogenetics.

[2]  H. Eisen,et al.  Functional differences between memory and naive CD8 T cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M F del Guercio,et al.  Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. , 1996, Human immunology.

[4]  J. Berzofsky,et al.  Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. , 1998, The Journal of clinical investigation.

[5]  J. Sidney,et al.  HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. , 1998, Current opinion in immunology.

[6]  M F del Guercio,et al.  Several HLA alleles share overlapping peptide specificities. , 1995, Journal of immunology.

[7]  J. Sidney,et al.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.

[8]  Hans-Georg Rammensee,et al.  MHC Ligands and Peptide Motifs , 1998, Molecular Biology Intelligence Unit.

[9]  H. Eisen,et al.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. , 1996, Immunity.

[10]  J. Sidney,et al.  Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. , 1999, Human immunology.

[11]  R. Hartzman,et al.  Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. , 2000, Human immunology.

[12]  C Oseroff,et al.  On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. , 1991, Journal of immunology.

[13]  J. Frelinger,et al.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[15]  R W Chesnut,et al.  Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. , 1997, Immunity.

[16]  F. Marincola,et al.  Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. , 1996, Journal of immunology.

[17]  P. Rovero,et al.  Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha chains. , 1993, Human immunology.

[18]  C. Bordignon,et al.  Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. , 1996, Journal of immunology.

[19]  R W Chesnut,et al.  Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. , 1997, The Journal of clinical investigation.

[20]  W R Mayr,et al.  Nomenclature for factors of the HLA system, 1996. , 1997, Vox sanguinis.

[21]  Ronald N. Germain,et al.  MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation , 1994, Cell.

[22]  A Sette,et al.  Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. , 1996, Immunology today.

[23]  John Sidney,et al.  Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes , 1997, Immunogenetics.

[24]  S. H. van der Burg,et al.  Analogues of CTL epitopes with improved MHC class‐I binding capacity elicit anti‐melanoma CTL recognizing the wild‐type epitope , 1997, International journal of cancer.

[25]  J. Sidney,et al.  The HLA-A0207 Peptide Binding Repertoire is Limited to a Subset of the A0201 Repertoire , 1997 .

[26]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[27]  M F del Guercio,et al.  Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. , 1995, Journal of immunology.

[28]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[29]  A Sette,et al.  Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.

[30]  S. Kuhara,et al.  Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. , 1995, Journal of immunology.

[31]  H. Grey,et al.  Chemistry of peptide interactions with MHC proteins , 1992, Current Biology.

[32]  M F del Guercio,et al.  Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. , 1996, Journal of immunology.

[33]  P. Stastny,et al.  DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. , 1992, Human immunology.

[34]  G. Ferrara,et al.  Molecular features of the hepatitis B virus nucleocapsid T‐cell epitope 18‐27: Interaction with HLA and T‐cell receptor , 1997, Hepatology.

[35]  Steven G.E. Marsh,et al.  Nomenclature for factors of the HLA system , 1975 .

[36]  A Sette,et al.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.

[37]  John Sidney,et al.  Measurement of MHC/Peptide Interactions by Gel Filtration , 1999, Current protocols in immunology.

[38]  R. Offringa,et al.  Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma , 1999, European journal of immunology.

[39]  D. Madden The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.

[40]  A Sette,et al.  Definition of specific peptide motifs for four major HLA-A alleles. , 1994, Journal of immunology.

[41]  J. Berzofsky,et al.  Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Sette,et al.  The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.

[43]  S. Burrows,et al.  Identification of cytotoxic T cell epitopes within Epstein‐Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype‐restricted immune recognition of EBV‐infected cells by LMP1‐specific cytotoxic T lymphocytes , 1998, European journal of immunology.

[44]  J. Skolnick,et al.  Application of an artificial neural network to predict specific class I MHC binding peptide sequences , 1998, Nature Biotechnology.

[45]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[46]  K. Parker,et al.  Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. , 1992, Journal of immunology.

[47]  M. Bunce,et al.  Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. , 1995, Tissue antigens.

[48]  G Hermanson,et al.  Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. , 1995, Journal of immunology.

[49]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.